TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A recent cardiovascular research roundup describes a randomized study reporting short-term blood-pressure benefits from isometric exercise performed three times weekly, and a small trial comparing two drug-coated balloons for severe peripheral artery disease. A separate preclinical study described semaglutide as a plausible therapy for reversing obesity-associated HFpEF.
A cardiovascular research roundup dated Oct. 6 reported that a randomized study found short-term blood-pressure-lowering benefits with isometric exercises such as squats and planks performed three times a week. The roundup also described a small head-to-head comparison of drug-coated balloons for severe peripheral artery disease and a preclinical semaglutide study involving heart failure with preserved ejection fraction (HFpEF).
The exercise finding came from a randomized study in BMJ Open Sport & Exercise Medicine. The report described three weekly sessions of isometric exercise training as the schedule that best produced short-term blood-pressure benefits. Isometric exercises involve holding muscle tension without repeated movement, as in a plank or a squat held in position. The supplied report does not give the size of the blood-pressure change, the number of participants or further details about the duration of the benefits.
A small trial in people receiving endovascular treatment for severe peripheral artery disease compared sirolimus- and paclitaxel-eluting drug-coated balloons. According to the roundup, the sirolimus balloon was better for restoring endothelial function. That difference did not materially change patency or target lesion revascularization at 12 months. The roundup associated the findings with the Journal of the American Heart Association.
The HFpEF item was based on a preclinical study associated with the European Heart Journal. Researchers described semaglutide, sold as Ozempic and Wegovy, as a plausible therapy for reversing obesity-associated cardiometabolic HFpEF. The roundup also noted an American College of Cardiology scientific statement recommending minimally processed plant foods and healthy sources of fats and proteins.
What the Findings Could Change
The roundup reports findings from studies of isometric exercise, drug-coated balloons and semaglutide. The exercise study reported short-term blood-pressure benefits with isometric training performed three times weekly, but the report does not provide further details about the size or duration of the effect.
In the small balloon trial, the sirolimus device was reported to be better for restoring endothelial function. The roundup said this did not materially change 12-month vessel patency or target lesion revascularization.
For HFpEF, the semaglutide finding came from a preclinical study. Researchers described the drug as a plausible therapy for reversing obesity-associated cardiometabolic HFpEF.
isometric exercise resistance bands
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Three Separate Lines of Evidence
The items appeared in a MedPage Today cardiovascular roundup by senior staff writer Nicole Lou, dated Oct. 6, 2026. The roundup covered developments from studies and other sources across cardiology. It described a randomized exercise study, a small balloon trial and a preclinical HFpEF study.
Among the other developments, the roundup cited an updated meta-analysis that included the CHAMPION-AF study and favored percutaneous left atrial appendage closure instead of relying on oral anticoagulation for people with atrial fibrillation. It also reported that a post hoc analysis of PREVENT suggested the benefit of preventive coronary intervention may hinge on whether someone has lipid-rich plaques to begin with. These findings are separate from the exercise, balloon and HFpEF items.
The roundup also described a retraction-related warning: an erroneous clinical trial registration number was identified as a major red flag for a published study of Watchman FLX left atrial appendage occlusion guided exclusively by fluoroscopy. That item underscores the importance of checking study records and methods, but the supplied report does not provide further details about the registration discrepancy.
“Isometric exercise training — such as squats and plank exercises — was best done three times a week for short-term blood pressure-lowering benefits.”
— MedPage Today report, summarizing the randomized exercise study
blood pressure squat and plank workout equipment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Current Evidence
The supplied report does not state the exercise trial’s participant count, precise blood-pressure changes, follow-up period or whether benefits persisted after training stopped. It also does not provide enough detail to determine how the three-times-weekly schedule compares with other exercise plans or how it performs alongside standard treatment.
For the drug-coated balloons, the trial was described as small, and the report gives no participant count or detailed effect estimates. Longer follow-up and larger comparisons would be needed to clarify whether the endothelial-function difference leads to meaningful clinical outcomes. For semaglutide, the central limitation is clearer: the evidence cited is preclinical, and human benefit for HFpEF remains unconfirmed. The roundup does not identify a clinical trial or timetable for testing that specific possibility.
semaglutide weight loss medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Evidence Needed Before Care Changes
The next step for the isometric-exercise finding is replication and fuller reporting of the size and persistence of the blood-pressure effect, including comparisons with other exercise approaches. Until stronger evidence is available, the roundup supports viewing the schedule as a study result, not a stand-alone prescription.
For the balloon comparison, further follow-up and larger trials could show whether the difference in endothelial function affects vessel outcomes beyond 12 months. For semaglutide and HFpEF, clinical studies would be needed to test whether the preclinical signal applies to patients and to establish benefits and risks. The source material does not announce a specific next trial or regulatory step for either line of research.
drug-coated balloons for peripheral artery disease
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the exercise study report?
A randomized study reported short-term blood-pressure-lowering benefits with isometric training, including squats and planks, performed three times a week. The supplied roundup does not give the size or duration of the effect beyond describing it as short term.
Did one drug-coated balloon produce better clinical outcomes?
The sirolimus-eluting balloon was reported to perform better in restoring endothelial function. The small trial did not show a material difference in patency or target lesion revascularization at 12 months.
Has semaglutide been shown to reverse HFpEF in patients?
No. The cited result was preclinical and described semaglutide as a plausible therapy for obesity-associated cardiometabolic HFpEF. The roundup does not report evidence that it reverses the condition in people.
Do these findings change current treatment guidance?
The roundup does not report a treatment-guideline change based on these three findings. The exercise result is short term, the balloon trial is small, and the semaglutide finding is preclinical; each requires further evidence before conclusions about routine care can be drawn.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
